Cases
Ocular Therapeutix, Inc. (NASDAQ : OCUL)
Securities Class Action
Overview
Overview
- Date:
- 7/10/2017
- Company Name:
- Ocular Therapeutix, Inc.
- Stock Symbol:
- OCUL
- Class Period:
- FROM 3/10/2016 TO 7/11/2017
- Status:
- Closed/Complete
- Court:
- U.S. Bankruptcy Court: District of New Jersey
NEW YORK, July 10, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Ocular Therapeutix, Inc. (OTC: OCUL) securities between March 10, 2016 and July 6, 2017 (the “Class Period”). Investors have until September 5, 2017 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On July 6, 2017, Seeking Alpha published an article claiming that Ocular had been misleading investors about manufacturing issues with its product, DEXTENZA, including the claim that more than 50% of the lots manufactured by Ocular contained bad product. Following this news, shares of Ocular Thereapeutix fell $3.06 over two trading days, or over 30%, to close at $7.12 per share on July 7, 2017.
The Complaint alleges that throughout the Class Period, the Company made false and/or misleading statements and/or failed to disclose that: (1) Ocular Therapeutix’s management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product; (2) such manufacturing issues could imperil the approval of DEXTENZA by the FDA; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Ocular Therapeutix securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On July 6, 2017, Seeking Alpha published an article claiming that Ocular had been misleading investors about manufacturing issues with its product, DEXTENZA, including the claim that more than 50% of the lots manufactured by Ocular contained bad product. Following this news, shares of Ocular Thereapeutix fell $3.06 over two trading days, or over 30%, to close at $7.12 per share on July 7, 2017.
The Complaint alleges that throughout the Class Period, the Company made false and/or misleading statements and/or failed to disclose that: (1) Ocular Therapeutix’s management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product; (2) such manufacturing issues could imperil the approval of DEXTENZA by the FDA; and (3) as a result, Defendants’ public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired Ocular Therapeutix securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.